中访网数据广州白云山医药集团股份有限公司（证券代码：600332）于12月22日发布了2025年度“提质增效重回报”行动方案的半年度评估报告。报告显示，公司聚焦主业经营稳健，前三季度营收与净利润实现双增长，同时通过增加分红频次、加大创新研发与资本运作力度，积极回报投资者并提升核心竞争力。在经营与效益方面，公司2025年前三季度营业收入同比增长4.31%，净利润同比增长4.78%。公司深耕医药健康...
Source Link中访网数据广州白云山医药集团股份有限公司（证券代码：600332）于12月22日发布了2025年度“提质增效重回报”行动方案的半年度评估报告。报告显示，公司聚焦主业经营稳健，前三季度营收与净利润实现双增长，同时通过增加分红频次、加大创新研发与资本运作力度，积极回报投资者并提升核心竞争力。在经营与效益方面，公司2025年前三季度营业收入同比增长4.31%，净利润同比增长4.78%。公司深耕医药健康...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.